Lupin: USFDA completes inspection of Nashik plant with zero observation

Pharma major Lupin announced the successful completion of an inspection carried out by the US FDA at its Nagpur, Maharashtra, India facility, on Friday. The inspection concluded without any observation.

This inspection was a product-specific pre-approval inspection. Lupin's Nagpur facility is the company's latest site and manufactures oral solid dosage products. The site also houses Lupin's state-of-the-art injectable manufacturing facility.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded, biotechnology products and APIs, globally. The company is a significant player in the cardiovascular, diabetology, asthma, pediatric, CNS, GI, anti-infective and NSAID space and holds a global leadership position in the anti-TB segment.

On Friday, at 13.08 hours, the stock of Lupin was trading at Rs. 972.65 per share up by Rs. 16.30 or 1.63 per cent. While the benchmark index BSE Sensex was at 37,980, up by 261 points or 0.69 per cent. The stock with a face value of Rs. 2 has a 52-week high of Rs. 1,090 and corresponding low of Rs. 723 per share.